334 Gene Expression Analysis of Human Sarcoma Tissues to Explore Clinical Outcomes of mTOR Inhibition with Ridaforolimus: Correlative Science From the Phase III SUCCEED Trial Testing Maintenance Therapy for Metastatic Disease
T. Zhang, Jean‐Yves Blay(Université Claude Bernard Lyon 1), George D. Demetri(American Society of Clinical Oncology), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), C. Van Sant, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), B. Haines, Victor M. Rivera(Ariadne Diagnostics (United States))
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k